Mounjaro is the brand name for tirzepatide, an FDA-approved dual GLP-1/GIP agonist that Eli Lilly sells for type 2 diabetes. Retatrutide is a newer Eli Lilly molecule that adds a third target, the glucagon receptor, making it a triple agonist. In trials, retatrutide produced larger average weight loss than tirzepatide, but it remains investigational and is not FDA-approved as of June 2026. So the short answer is this: Mounjaro is available by prescription today, while retatrutide is the more powerful candidate still working through Phase 3.
This comparison is a bit asymmetric because one drug is on pharmacy shelves and the other is still in trials. Below you will find what each molecule does, the actual numbers from the clinical record, and how dosing, blood-sugar effects, availability, and cost stack up.
Quick clarification: Mounjaro, Zepbound, and tirzepatide
Three names, one molecule. Tirzepatide is the active drug. Eli Lilly markets the same compound under two brands:
- Mounjaro is tirzepatide approved for type 2 diabetes (FDA approval May 2022).
- Zepbound is the same tirzepatide molecule approved for chronic weight management (FDA approval late 2023).
If you searched "Mounjaro" because you want weight loss, the product your clinician would prescribe for that indication is usually Zepbound, though the underlying chemistry is identical. Retatrutide has no brand name yet because it has not been approved or launched.
Mechanism: dual agonist vs triple agonist
This is the core difference. Both drugs are gut-hormone mimics, but retatrutide hits one more receptor.
- Mounjaro (tirzepatide) activates two receptors: GLP-1 and GIP. GLP-1 slows gastric emptying, curbs appetite, and boosts glucose-dependent insulin release. GIP adds further insulin and appetite effects. Lilly nicknamed this "twincretin" activity.
- Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The first two work much like tirzepatide. The added glucagon receptor agonism is the twist. Glucagon signaling can increase energy expenditure and influence liver fat metabolism, which is thought to push weight loss higher than dual agonists alone.
The practical takeaway: tirzepatide is a proven dual mechanism, while retatrutide bets that adding glucagon agonism produces more weight loss and metabolic benefit. The early data support that bet, but glucagon agonism is also why researchers watch heart rate and blood-sugar dynamics closely, since glucagon can raise both.
Side-by-side comparison
| Feature | Mounjaro (tirzepatide) | Retatrutide |
|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly |
| Drug class | Dual GLP-1/GIP agonist | Triple GLP-1/GIP/glucagon agonist |
| FDA status | Approved (type 2 diabetes, 2022) | Investigational, Phase 3, not approved |
| Weight-loss brand of same molecule | Zepbound | None yet |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose range | 2.5 mg to 15 mg weekly | 1 mg to 12 mg weekly (trial doses) |
| Peak trial weight loss | ~20.9% at 72 weeks (SURMOUNT-1) | ~24.2% at 48 weeks (Phase 2); ~30.3% at 104 weeks (Phase 3 topline) |
| A1c reduction | Up to ~2.3% (SURPASS) | Improvements seen in trials, not yet labeled |
| Availability | Prescription, pharmacies | Trials only; no legal approved supply |
| Cost | List price roughly $1,000+/month without insurance | No approved price; not commercially sold |
Weight-loss results: what the trials actually showed
Retatrutide's headline numbers are higher, but the trial designs differ, so direct comparison is approximate rather than head-to-head.
Mounjaro / tirzepatide
- SURMOUNT-1 (adults with obesity, no diabetes): average weight reduction of about 19.5% at the 10 mg dose and 20.9% at the 15 mg dose by week 72.
- SURMOUNT-2 (adults with obesity and type 2 diabetes): about 12.8% at 10 mg and 14.7% at 15 mg.
- Tirzepatide for weight loss is delivered under the Zepbound brand, while Mounjaro itself carries the diabetes indication.
Retatrutide
- Phase 2 TRIUMPH (NEJM, 2023): 338 adults with obesity or overweight without type 2 diabetes, randomized to placebo or 1, 4, 8, or 12 mg weekly. The 12 mg dose produced a mean reduction of about 17.5% (roughly 41 lb) at 24 weeks and about 24.2% (roughly 58 lb) at 48 weeks. Notably, participants had not yet hit a weight plateau when the study ended, suggesting the curve was still falling.
- Phase 3 TRIUMPH-1 topline: In a 2,339-participant trial, Lilly reported mean weight loss of about 25.0% at the 12 mg dose by week 80 on the treatment-regimen estimand, rising toward roughly 28.3% among participants who stayed on treatment, versus about 3.9% on placebo. Participants with a higher starting BMI who continued reached up to about 30.3% (an average of roughly 85 lb) by 104 weeks.
- TRIUMPH-4 (obesity with knee osteoarthritis): about 28.7% weight loss at the 12 mg dose over 68 weeks, versus about 2.1% on placebo.
So in round numbers, tirzepatide tops out near 20 to 21% in its obesity trial, while retatrutide reached the mid-20s in Phase 2 and roughly 30% in early Phase 3 readouts. That gap is the main reason retatrutide is generating so much interest. For more detail on the trial program, see our retatrutide clinical trial summary.
Blood-sugar and metabolic effects
Mounjaro's primary job is glycemic control. In the SURPASS program, tirzepatide lowered A1c by up to roughly 2.3%, and in SURPASS-2 it outperformed semaglutide at every dose tested. That is why tirzepatide carries a type 2 diabetes indication and retatrutide does not yet.
Retatrutide also improved glycemic and cardiometabolic markers in its Phase 2 trial. Treatment was associated with better systolic and diastolic blood pressure, triglycerides, LDL cholesterol, total cholesterol, HbA1c, and fasting glucose and insulin at weeks 24 and 48. These were exploratory endpoints, however, not the regulatory-grade diabetes outcomes tirzepatide already has. A dedicated diabetes trial, TRIUMPH-2, evaluates retatrutide in adults with obesity or overweight and type 2 diabetes, and a separate cardiovascular trial, TRIUMPH-3, studies people with established cardiovascular disease. Both are part of the Phase 3 program, and their full results will shape any future diabetes or heart-related claims. Because the glucagon receptor influences hepatic glucose output, retatrutide's blood-sugar profile is being studied carefully rather than assumed.
Dosing and titration
Both drugs are once-weekly subcutaneous injections that start low and step up to limit gastrointestinal side effects.
- Mounjaro: start at 2.5 mg weekly, increase by 2.5 mg every four weeks as tolerated, to a maximum of 15 mg weekly. The 2.5 mg dose is a starter, not a therapeutic target.
- Retatrutide: in trials, weekly doses ranged from 1 mg up to 12 mg, with gradual escalation. Because retatrutide is not approved, there is no FDA-sanctioned dosing label, and any "protocol" circulating online is extrapolated from trial designs rather than an official regimen.
If you want the trial-based escalation details, see our retatrutide dosage guide.
Side effects and tolerability
The side-effect profiles overlap heavily because both drugs lean on GLP-1 and GIP activity.
- Both: nausea, diarrhea, vomiting, constipation, decreased appetite, and acid reflux are the most common complaints. These are usually mild to moderate and cluster during dose escalation. Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents, and GLP-1-class drugs share precautions around pancreatitis and gallbladder issues.
- Retatrutide specifics: gastrointestinal events were the most frequently reported adverse events in Phase 2 and were generally manageable during titration. The added glucagon agonism means heart rate and glucose handling get extra scrutiny in ongoing trials.
Because retatrutide has a shorter human safety record, its long-term tolerability is still being established. See retatrutide side effects for the current picture.
Availability and legal status
This is the most decisive practical difference.
- Mounjaro is available now with a prescription through standard pharmacies and supports a real diabetes indication.
- Retatrutide is not commercially available. It is investigational and can only be accessed legitimately through enrolled clinical trials. Eli Lilly's estimated FDA submission window is late 2026 or early 2027, with a possible approval no earlier than late 2027, though no official regulatory timeline has been confirmed.
You will see "retatrutide" sold by research-chemical sellers and compounding channels. Those products are not FDA-approved, are not quality-assured the way an approved drug is, and carry real risks around purity and dosing. We cover the timeline and the access risks in when will retatrutide be available.
Cost
Mounjaro's list price runs roughly $1,000 or more per month without insurance, though coverage, savings cards, and the Zepbound version change what people actually pay. Retatrutide has no approved retail price because it is not sold commercially. Any figure you see attached to "retatrutide cost" today reflects gray-market or compounded pricing, not an established list price. For context on the moving parts, see retatrutide cost.
Which is "better"?
It depends on what "better" means and on timing.
- If you need a treatment available today, especially for type 2 diabetes, Mounjaro is the proven, approved choice with years of data.
- If you are tracking the most powerful future option, retatrutide's triple-agonist mechanism delivered larger weight loss in trials and may eventually set a new ceiling, but it is not something you can legally and safely obtain outside a trial right now.
The honest framing is that you are comparing a finished product against a promising candidate. Retatrutide may well outperform tirzepatide on weight loss when the full Phase 3 record is in, yet "more potent in trials" is not the same as "approved, dosed, and safe for you today."
FAQ
Is retatrutide stronger than Mounjaro?
In clinical trials, retatrutide produced larger average weight loss (mid-20s percent in Phase 2 and roughly 30% in early Phase 3) than tirzepatide's roughly 20 to 21% in SURMOUNT-1. But the trials are not a direct head-to-head, and retatrutide is still investigational, so "stronger on paper" comes with that caveat. See our retatrutide vs tirzepatide comparison for the molecule-level detail.
Is retatrutide FDA-approved yet?
No. As of June 2026, retatrutide is in Phase 3 trials and has not been approved by the FDA. Eli Lilly has signaled a possible submission in late 2026 or 2027, but nothing is finalized.
Are Mounjaro and Zepbound the same as retatrutide?
No. Mounjaro and Zepbound are both tirzepatide, a dual GLP-1/GIP agonist. Retatrutide is a different, triple agonist that also targets the glucagon receptor.
Can I switch from Mounjaro to retatrutide?
Not through legitimate channels yet, because retatrutide is not approved or prescribable outside trials. Any switch decision belongs with a clinician once retatrutide is available, factoring in your titration history and tolerability.
How does retatrutide compare to semaglutide too?
Retatrutide's trial weight loss exceeded the figures typically seen with semaglutide as well, which lands near 15% in its STEP obesity trials. As always, those are separate trials rather than a single head-to-head study, so the comparison is directional. Semaglutide and tirzepatide are both approved today, while retatrutide is not.
This article is for informational purposes only and is not medical advice; talk to a licensed clinician before starting, stopping, or changing any medication.
